This exciting program is for Principal Investigators who are employed full-time by Weill Cornell Medicine. Tri-I TDI partners with Takeda Pharmaceuticals to advance early-stage projects, that have the potential to benefit patients, to proof-of-concept studies.
The program’s objective is to develop novel compounds that elucidate fundamental physiologic and pathological processes, improve efficiency in drug development, create intellectual property that can be further developed by industry collaborators, and translate basic research into clinical application.
Only small molecule chemical compounds will be considered, which excludes antibody, protein and any other biologic therapeutics.
Log into your VPN to access the application page for more details and application process: https://intranet.tritdi.org/applications/small-molecules/.